We show that TPST-1495 was significantly more potent than single EP receptor antagonists or COX-2 inhibition at inducing immune activation, antitumor immunity, and tumor clearance in multiple models of human malignancies, highlighting the redundancy of EP2 and EP4 signaling in the tumor and the necessity of dual receptor blockade. Here, PTGER4 is linked to neoplasm.